NOVAVAX INC (NVAX) Financials
Annual revenue, profitability and per-share results for NOVAVAX INC, as reported in SEC filings.
Revenue • FY2025
$1.12B
▲ 64.7%YoY
Net income • FY2025
$440.3M
▲ 334.8%YoY
Gross margin • FY2025
93.5%
Diluted EPS • FY2025
$2.58
▲ 309.8%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.12B | $440.3M | $1.05B | $2.58 | -$250.19M | 40.3% | +64.7% |
| FY2024 | $682.16M | -$187.5M | $479.42M | -$1.23 | -$100.32M | -36.5% | -30.6% |
| FY2023 | $983.71M | -$545.06M | $639.94M | -$5.41 | -$767.74M | -57.6% | -50.4% |
| FY2022 | $1.98B | -$657.94M | $1.08B | -$8.42 | -$504.99M | -32.5% | +72.9% |
Figures as reported in NOVAVAX INC's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Financials for companies related to NVAX
Never miss a NVAX filing.
Get an email when NVAX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.